Adjuvant Chemotherapy

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed the “practice-changing” results from the OUTBACK trial.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about the OUTBACK trial presented at the ASCO Annual Meeting.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.

A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer.

Adjuvant chemotherapy following chemoradiation did not prolong OS or PFS compared with chemoradiation alone among women with locally advanced cervical cancer, according to results of the randomized phase 3 OUTBACK study.

Menopausal status may determine which women with lymph node-positive early breast cancer and low recurrence scores require adjuvant chemotherapy, according to findings presented at the virtual San Antonio Breast Cancer Symposium.

Pancreatic ductal adenocarcinoma historically has been a challenging cancer to treat, and often is not detected until it has progressed and metastasized. Some subtypes respond well to chemotherapy, whereas others are resistant.

Adjuvant chemotherapy plus endocrine therapy appeared to produce early — but not sustained — cognitive impairment compared with endocrine therapy alone for women with early breast cancer, according to patient-reported data from the TAILORx trial published in Journal of Clinical Oncology.

Circulating tumor DNA has shown great promise as a blood-based, prognostic biomarker for patients with colon cancer, with detectable levels after resection considered an indicator of elevated risk for recurrence.

The combination of gemcitabine and platinum chemotherapy administered within 90 days after nephroureterectomy significantly extended DFS among patients with locally advanced upper tract urothelial carcinoma, according to results of the randomized phase 3 POUT trial published in The Lancet.